Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2008-06-03 10:02:00 |
Versijas komentārs | |
Teksts |
On the 3rd of June Joint-stock company Grindeks celebrates Ridgepole celebrations of the new waste water purification plant building, thus expressing support to the World Environment Day whose theme this year is Green Cities. The Purification plant is being constructed, in order to prevent efficiently the possible harm to the environment. Construction of the purification plant is one of the most significant development projects of the company in 2008. Construction was started in September, 2007, and it is planned to be finished by the end of 2008. The total investments for implementation of the project will be almost 2.5 million lats. Chairman of the Council of JSC Grindeks Kirovs Lipmans stresses: „The rapid growth of Grindeks allows investing of increasingly greater means in development and improvement of production infrastructure. Construction of technologically modern purification plant is a purposefully planned investment project, in order that we, increasing production capacities, could ensure not only a stable increase of Grindeks’s turnover, but also to care efficiently for environment protection.” Chairman of the Board of JSC Grindeks Jānis Romanovskis emphasizes the responsibility of the company in front of environment and society: „We are aware that we are working in The technological project of purification plant is being developed by Swedish company AnoxKaldnes which has an important experience of implementation of specific pharmacy sewage purification projects for other big pharmaceutical companies. Construction work is carried out by Latvian construction company Ekotehnoloģijas. Overview of JSC Grindeks JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main activity is research, development, production and sales of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. Laila Kļaviņa, |
Pielikumi |
|